This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Markovic, S. N. Articles by Murasko, D. M. Search for Related Content PubMed PubMed Citation Articles by Markovic, S. N. Articles by Murasko, D. M.

Role of Natural Killer and T-Cells in Interferon Induced Inhibition of Spontaneous Metastases of the B16F10L Murine Melanoma¹

Department of Microbiology and Immunology, The Medical College of Pennsylvania, Philadelphia, Pennsylvania 19129 [S. N. M., D. M. M.]

We have previously demonstrated that interferon (IFN) treatment of mice bearing the spontaneously metastasizing B16F10L murine melanoma on days -5 to -1 prior to surgical removal (day 0) of the primary tumor resulted in survival of >50% of treated mice. The antitumor effect was correlated with an early increase of natural killer (NK) cell cytotoxicity followed by a later developing specific cytolytic T-cell response. The purpose of this study was to establish definitively the roles of NK, CD4, and CD8 cells as mediators of the antitumor/antimetastatic effects of IFN. Mice were depleted of NK, CD4, and/or CD8 cells during the period of IFN treatment by administration of anti-asialo-G_M1, anti-L3T4, and/or anti-Lyt-2 antisera. Depletion of NK cells, alone or in combination with T-cells, eliminated the protective effect of IFN treatment. Depletion of both CD4 and CD8 cells, however, did not significantly alter the therapeutic effect of IFN therapy. Collectively, these data conclusively demonstrated the importance of NK cells as mediators of the IFN induced antitumor state. However, in mice depleted of CD4 cells alone, the protective effect of IFN was eliminated, in spite of the presence of intact NK cells. In vitro analysis of NK cytotoxicity on day 1 after surgery demonstrated (a) a lack of IFN induced stimulation of NK activity in CD4 depleted mice and (b) a significant increase in both baseline and IFN induced NK cytotoxicity in CD8 depleted mice. These data suggested a CD8 cell mediated inhibition of NK activity/stimulation in CD4 depleted mice, possibly responsible for the lack of response to IFN therapy in that group.

These results demonstrate the importance of not only individual components of the immune system but also the interaction of these components in both the natural and IFN induced control of spontaneous B16F10L metastases.

¹ This work has been supported by NIH Grant CA43386.

² To whom requests for reprints should be addressed, at Department of Microbiology and Immunology, The Medical College of Pennsylvania, 3300 Henry Ave., Philadelphia, PA 19129.

Received 9/24/90. Accepted 12/ 5/90.

This article has been cited by other articles:

				D. Kamimura, Y. Sawa, M. Sato, E. Agung, T. Hirano, and M. Murakami IL-2 In Vivo Activities and Antitumor Efficacy Enhanced by an Anti-IL-2 mAb J. Immunol., July 1, 2006; 177(1): 306 - 314. [Abstract] [Full Text] [PDF]

				S. V. Vaidya, S. E. Stepp, M. E. McNerney, J.-K. Lee, M. Bennett, K.-M. Lee, C. L. Stewart, V. Kumar, and P. A. Mathew Targeted Disruption of the 2B4 Gene in Mice Reveals an In Vivo Role of 2B4 (CD244) in the Rejection of B16 Melanoma Cells J. Immunol., January 15, 2005; 174(2): 800 - 807. [Abstract] [Full Text] [PDF]

				M. S. Merchant, X. Yang, F. Melchionda, M. Romero, R. Klein, C. J. Thiele, M. Tsokos, H. U. Kontny, and C. L. Mackall Interferon {gamma} Enhances the Effectiveness of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor Agonists in a Xenograft Model of Ewing's Sarcoma Cancer Res., November 15, 2004; 64(22): 8349 - 8356. [Abstract] [Full Text] [PDF]

				D. J. Herzyk, E. R. Gore, R. Polsky, K. L. Nadwodny, C. C. Maier, S. Liu, T. K. Hart, A. G. Harmsen, and P. J. Bugelski Immunomodulatory Effects of Anti-CD4 Antibody in Host Resistance against Infections and Tumors in Human CD4 Transgenic Mice Infect. Immun., February 1, 2001; 69(2): 1032 - 1043. [Abstract] [Full Text] [PDF]

				J. G. Turner, A. L. Rakhmilevich, L. Burdelya, Z. Neal, M. Imboden, P. M. Sondel, and H. Yu Anti-CD40 Antibody Induces Antitumor and Antimetastatic Effects: The Role of NK Cells J. Immunol., January 1, 2001; 166(1): 89 - 94. [Abstract] [Full Text] [PDF]

				P J Bugelskil, D J Herzykl, S Rehm, A G Harmsen, E V Gore, D M Williams, B E Maleeff, A M Badger, A Truneh, S R O'Brien, et al. Preclinical development of keliximab, a PrimatizedTM anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies Human and Experimental Toxicology, April 1, 2000; 19(4): 230 - 243. [Abstract] [PDF]

				J. M. Davis, M. L. Kohut, D. A. Jackson, L. H. Colbert, E. P. Mayer, and A. Ghaffar Exercise effects on lung tumor metastases and in vitro alveolar macrophage antitumor cytotoxicity Am J Physiol Regulatory Integrative Comp Physiol, May 1, 1998; 274(5): R1454 - R1459. [Abstract] [Full Text] [PDF]